Selinexor Application Scope

Selinexor is an oral selective inhibitor of nuclear export (SINE) that restores tumor suppressor function and induces apoptosis in cancer cells.
Indications:

Relapsed/refractory multiple myeloma (MM) with prior ≥4 therapies, in combination with dexamethasone.
Relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after ≥2 prior systemic treatments.
xpovio selinexor

Selinexor Characteristics

Ingredients: Active ingredient: Selinexor
Excipients: microcrystalline cellulose, sodium starch glycolate, magnesium stearate, etc.
Properties: White to off-white film-coated tablets.
Packaging Specification: Tablets, 20 mg or 40 mg, blister packs.
Storage: Store at room temperature, 20–25°C. Protect from moisture and light.
Expiry Date: As indicated on the package. Typically 24–36 months.
Executive Standard: Enterprise standard or regulatory approval standard.
Approval Number: According to local regulatory agency (e.g., FDA, EMA, NMPA).
Date of Revision: As stated in the package insert.
Manufacturer: Karyopharm Therapeutics Inc.

Guidelines for the Use of Xpovio

Dosage and Administration:
- Recommended Dose: For relapsed/refractory multiple myeloma: 80 mg orally (two 40 mg tablets) taken with dexamethasone on Day 1 and Day 3 of each week.
  For relapsed/refractory DLBCL: 60 mg orally (three 20 mg tablets) on Day 1 and Day 3 of each week.
- Administration: Take with water, swallow whole. Do not crush, chew, or split tablets.
- Missed Dose: If a dose is missed, take the next scheduled dose at the regular time. Do not double the dose.
Adverse Reactions:
- Common Adverse Reactions:
  - Nausea, vomiting, diarrhea
  - Fatigue, decreased appetite, weight loss
  - Thrombocytopenia, anemia, neutropenia
  - Hyponatremia
- Serious Adverse Reactions:
  - Severe thrombocytopenia with bleeding
  - Severe neutropenia with infection
  - Gastrointestinal toxicity (severe nausea, vomiting, diarrhea, dehydration)
  - Neurological symptoms (confusion, dizziness, syncope)
Contraindications:
- Known hypersensitivity to Selinexor or any excipients.
- Pregnancy and breastfeeding.
Precautions:
- Monitor complete blood counts regularly.
- Monitor serum sodium levels.
- Provide prophylaxis and supportive care for nausea, vomiting, and appetite loss.
- Use caution in patients with pre-existing cytopenias or severe organ dysfunction.

Selinexor Interactions

Concomitant use with strong CYP3A4 inducers may reduce efficacy.
Caution with drugs that increase risk of bleeding or thrombocytopenia.
Monitor closely when used with CNS depressants due to potential dizziness and confusion.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.